WO2009054439A1 - Pai-1産生抑制剤 - Google Patents

Pai-1産生抑制剤 Download PDF

Info

Publication number
WO2009054439A1
WO2009054439A1 PCT/JP2008/069207 JP2008069207W WO2009054439A1 WO 2009054439 A1 WO2009054439 A1 WO 2009054439A1 JP 2008069207 W JP2008069207 W JP 2008069207W WO 2009054439 A1 WO2009054439 A1 WO 2009054439A1
Authority
WO
WIPO (PCT)
Prior art keywords
pai
group
production inhibitor
benzene ring
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/069207
Other languages
English (en)
French (fr)
Inventor
Susumu Muto
Akiko Itai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Medicinal Molecular Design Inc IMMD
Original Assignee
Institute of Medicinal Molecular Design Inc IMMD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Medicinal Molecular Design Inc IMMD filed Critical Institute of Medicinal Molecular Design Inc IMMD
Priority to CA2703494A priority Critical patent/CA2703494A1/en
Priority to EP08842108A priority patent/EP2201946A4/en
Priority to BRPI0816560-2A priority patent/BRPI0816560A2/pt
Priority to JP2009538246A priority patent/JP5470046B2/ja
Priority to AU2008314979A priority patent/AU2008314979A1/en
Priority to CN2008801133696A priority patent/CN101842093B/zh
Publication of WO2009054439A1 publication Critical patent/WO2009054439A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

　下記の一般式(I)で表される化合物は、PAI-1産生抑制作用を有する。 【化１】 （式中、R1は例えば水素原子、4-(モルホルニル)カルボニル基などを表し、環Dは例えばベンゼン環又は置換基を有するベンゼン環を表し、フェニル基Eは例えばハロゲン原子、ハロゲン化アルキル基、アルキル基、ハロゲン化アルコキシ基、アルコキシ基などの置換基を有する。）
PCT/JP2008/069207 2007-10-23 2008-10-23 Pai-1産生抑制剤 Ceased WO2009054439A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2703494A CA2703494A1 (en) 2007-10-23 2008-10-23 Inhibitor of pai-1 production
EP08842108A EP2201946A4 (en) 2007-10-23 2008-10-23 HAMMER OF PAI-1 PRODUCTION
BRPI0816560-2A BRPI0816560A2 (pt) 2007-10-23 2008-10-23 Método de inibição de produção de pai-1 método para prevenção ou melhora de uma doença causada por uma super-produção de pai-1"
JP2009538246A JP5470046B2 (ja) 2007-10-23 2008-10-23 Ｐａｉ−１産生抑制剤
AU2008314979A AU2008314979A1 (en) 2007-10-23 2008-10-23 Inhibitor of PAI-1 production
CN2008801133696A CN101842093B (zh) 2007-10-23 2008-10-23 Pai-1产生抑制剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007275557 2007-10-23
JP2007-275557 2007-10-23

Publications (1)

Publication Number Publication Date
WO2009054439A1 true WO2009054439A1 (ja) 2009-04-30

Family

ID=40579541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/069207 Ceased WO2009054439A1 (ja) 2007-10-23 2008-10-23 Pai-1産生抑制剤

Country Status (9)

Country Link
EP (1) EP2201946A4 (ja)
JP (1) JP5470046B2 (ja)
KR (1) KR20100097113A (ja)
CN (2) CN101842093B (ja)
AU (1) AU2008314979A1 (ja)
BR (1) BRPI0816560A2 (ja)
CA (1) CA2703494A1 (ja)
RU (1) RU2010120675A (ja)
WO (1) WO2009054439A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501737A (ja) * 2009-08-14 2013-01-17 バイエル・クロップサイエンス・アーゲー 殺虫性カルボキサミド類
CN107207417A (zh) * 2014-11-13 2017-09-26 埃罗米克斯公司 新方法
US9827253B2 (en) 2013-11-06 2017-11-28 Aeromics, Inc. Prodrug salts
US9994514B2 (en) 2012-05-08 2018-06-12 Aeromics, Inc. Methods of treating cerebral edema and spinal cord edema
WO2024172001A1 (ja) * 2023-02-13 2024-08-22 本岡 知子 抗トリパノソーマ薬

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI725092B (zh) 2015-12-18 2021-04-21 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療糖尿病腎病或其相關病症之藥劑上的用途
WO2017101870A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性视网膜病变的方法
TWI624268B (zh) 2015-12-18 2018-05-21 Talengen Institute Of Life Sciences Co Ltd 纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑
WO2017101867A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
WO2018107688A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗脂肪肝的方法
JP7175270B2 (ja) 2016-12-15 2022-11-18 タレンゲン インターナショナル リミテッド グルカゴン、インスリンを正常なバランスに戻らせる方法
US11207387B2 (en) 2016-12-15 2021-12-28 Talengen International Limited Method and drug for preventing and treating obesity
CN108210896A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗高脂血症的药物及其用途
CN115504940A (zh) * 2021-06-23 2022-12-23 中国科学院上海药物研究所 一种酰胺类化合物、其制备方法和制药用途
CN113519544A (zh) * 2021-08-27 2021-10-22 皖南医学院 一种植物源杀螨剂及其制备方法和应用

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62501703A (ja) * 1984-11-29 1987-07-09 イタルファルマコ・エッセ・ピ・ア アミノ−サリチル酸誘導体、その塩、それらの製法およびそれらを含有する医薬組成物
WO1995021832A1 (en) 1994-02-14 1995-08-17 Xenova Limited Pharmaceutical piperazine compounds
WO1995032190A2 (en) 1994-05-24 1995-11-30 Xenova Limited Pharmaceutical diketopiperazine compounds
WO1999065449A2 (en) 1998-06-19 1999-12-23 Smithkline Beecham Corporation INHIBITORS OF TRANSCRIPTION FACTOR NF-λB
WO2002049632A1 (en) 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
GB2372740A (en) 2001-01-17 2002-09-04 Xenova Ltd Diketopiperazines
WO2003000671A1 (en) 2001-06-20 2003-01-03 Wyeth Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2003000253A1 (en) 2001-06-20 2003-01-03 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2003000258A1 (en) 2001-06-20 2003-01-03 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2003000684A1 (en) 2001-06-20 2003-01-03 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1)
WO2003100064A1 (en) 2002-05-29 2003-12-04 Kyowa Hakko Kogyo Co., Ltd. Novel ubiquitin ligase
WO2003103654A1 (ja) 2002-06-10 2003-12-18 株式会社医薬分子設計研究所 ＮＦ−κＢ活性化阻害剤
WO2003103658A1 (ja) 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
WO2004052856A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2004052893A2 (en) 2002-12-10 2004-06-24 Wyeth Substituted dihydropyrano indole-3,4-dione derivatives and 3-oxoacetic acid substituted 2-hydroxymethylindole derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2005026127A1 (ja) * 2003-09-11 2005-03-24 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤
WO2005030756A1 (en) 2003-09-25 2005-04-07 Wyeth Substituted pyrrole-indoles as inhibitors of pai-1
WO2005030204A1 (en) 2003-09-25 2005-04-07 Wyeth Substituted oxadiazolidinediones as pai-1 inhibitors
WO2005030192A1 (en) 2003-09-25 2005-04-07 Wyeth 4- (1h-indol-3-yl-methylideneaminoxy-propoxy) -benzioc acid derivatives and related compounds as pai-1 inhibitors for the treatment of impairment of the fibrinolytic system and of thrombisis
WO2005030715A1 (en) 2003-09-25 2005-04-07 Wyeth Substituted sulfonamide-indole-2-carboxylic acid derivatives as pai-1 inhibitors
WO2005030716A1 (en) 2003-09-25 2005-04-07 Wyeth Heterocyclic- or aryloxy, -thio or -amino substituted indoles-2-carboxylic acids or esters as pai-1
US20050124664A1 (en) 2003-10-30 2005-06-09 Eric Sartori Urea thiadiazole inhibitors of plasminogen activator inhibior-1
US20050124667A1 (en) 2003-10-30 2005-06-09 Eric Sartori Oxamide inhibitors of plasminogen activator inhibitor-1
US20050143384A1 (en) 2003-10-30 2005-06-30 Eric Sartori Amide thiadiazole inhibitors of plasminogen activator inhibitor-1
WO2006095713A1 (ja) * 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1493375A (en) * 1974-09-20 1977-11-30 Ici Ltd Salicylanilide derivatives
WO2003103648A1 (ja) * 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 糖尿病治療薬
EA010835B1 (ru) * 2002-06-10 2008-12-30 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения рака
ES2339138T3 (es) * 2004-11-24 2010-05-17 Eli Lilly And Company Derivados de eteres aromaticos utiles como inhibidores de la trombina.

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62501703A (ja) * 1984-11-29 1987-07-09 イタルファルマコ・エッセ・ピ・ア アミノ−サリチル酸誘導体、その塩、それらの製法およびそれらを含有する医薬組成物
WO1995021832A1 (en) 1994-02-14 1995-08-17 Xenova Limited Pharmaceutical piperazine compounds
WO1995032190A2 (en) 1994-05-24 1995-11-30 Xenova Limited Pharmaceutical diketopiperazine compounds
WO1999065449A2 (en) 1998-06-19 1999-12-23 Smithkline Beecham Corporation INHIBITORS OF TRANSCRIPTION FACTOR NF-λB
WO2002049632A1 (en) 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
GB2372740A (en) 2001-01-17 2002-09-04 Xenova Ltd Diketopiperazines
WO2003000671A1 (en) 2001-06-20 2003-01-03 Wyeth Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2003000253A1 (en) 2001-06-20 2003-01-03 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2003000258A1 (en) 2001-06-20 2003-01-03 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2003000684A1 (en) 2001-06-20 2003-01-03 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1)
WO2003100064A1 (en) 2002-05-29 2003-12-04 Kyowa Hakko Kogyo Co., Ltd. Novel ubiquitin ligase
WO2003103658A1 (ja) 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
WO2003103654A1 (ja) 2002-06-10 2003-12-18 株式会社医薬分子設計研究所 ＮＦ−κＢ活性化阻害剤
WO2004052856A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2004052893A2 (en) 2002-12-10 2004-06-24 Wyeth Substituted dihydropyrano indole-3,4-dione derivatives and 3-oxoacetic acid substituted 2-hydroxymethylindole derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2005026127A1 (ja) * 2003-09-11 2005-03-24 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤
EP1666469A1 (en) 2003-09-11 2006-06-07 Institute of Medicinal Molecular Design, Inc. Plasminogen activator inhibitor-1 inhibitor
WO2005030192A1 (en) 2003-09-25 2005-04-07 Wyeth 4- (1h-indol-3-yl-methylideneaminoxy-propoxy) -benzioc acid derivatives and related compounds as pai-1 inhibitors for the treatment of impairment of the fibrinolytic system and of thrombisis
WO2005030204A1 (en) 2003-09-25 2005-04-07 Wyeth Substituted oxadiazolidinediones as pai-1 inhibitors
WO2005030715A1 (en) 2003-09-25 2005-04-07 Wyeth Substituted sulfonamide-indole-2-carboxylic acid derivatives as pai-1 inhibitors
WO2005030716A1 (en) 2003-09-25 2005-04-07 Wyeth Heterocyclic- or aryloxy, -thio or -amino substituted indoles-2-carboxylic acids or esters as pai-1
WO2005030756A1 (en) 2003-09-25 2005-04-07 Wyeth Substituted pyrrole-indoles as inhibitors of pai-1
US20050124664A1 (en) 2003-10-30 2005-06-09 Eric Sartori Urea thiadiazole inhibitors of plasminogen activator inhibior-1
US20050124667A1 (en) 2003-10-30 2005-06-09 Eric Sartori Oxamide inhibitors of plasminogen activator inhibitor-1
US20050143384A1 (en) 2003-10-30 2005-06-30 Eric Sartori Amide thiadiazole inhibitors of plasminogen activator inhibitor-1
WO2006095713A1 (ja) * 2005-03-08 2006-09-14 Institute Of Medicinal Molecular Design. Inc. プラスミノゲンアクチベータインヒビター－１阻害剤

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 294, no. 5, 2002, pages 1155 - 1160
BIOCHEMISTRY, vol. 37, no. 5, 1998, pages 1227 - 1234
COMP. HEPATOL., vol. 6, 2 May 2007 (2007-05-02), pages 5
FASEB J., vol. 15, no. 10, 2001, pages 1840 - 1842
GEN. DIAGN. PATHOL., vol. 141, no. 1, 1995, pages 41 - 48
J. IMMUNOL., vol. 165, 2000, pages 3154 - 3161
J. IMMUNOL., vol. 165, no. 6, 2000, pages 3154 - 3161
J. MED CHEM., vol. 47, no. 14, 2004, pages 3491 - 3494
MOL. MED., vol. 2, no. 5, 1996, pages 568 - 582
NAT. MED., vol. 4, no. 8, 1998, pages 923 - 928
NATURE, vol. 346, no. 6279, 1990, pages 74 - 76
PATHOBIOLOGY, vol. 71, 2004, pages 295 - 301
PROC. NATL. ACAD. SCI. U. S. A., vol. 89, no. 15, 1992, pages 6998 - 7002
See also references of EP2201946A4 *
SPENCER J. R., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, 2002, pages 2023 - 2026, XP008131173 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013501737A (ja) * 2009-08-14 2013-01-17 バイエル・クロップサイエンス・アーゲー 殺虫性カルボキサミド類
US9227923B2 (en) 2009-08-14 2016-01-05 Bayer Intellectual Property Gmbh Pesticidal carboxamides
US12503425B2 (en) 2012-05-08 2025-12-23 Aeromics, Inc. Methods of treating or controlling cytotoxic cerebral edema
US11873266B2 (en) 2012-05-08 2024-01-16 Aeromics, Inc. Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke
US9994514B2 (en) 2012-05-08 2018-06-12 Aeromics, Inc. Methods of treating cerebral edema and spinal cord edema
US11084778B2 (en) 2012-05-08 2021-08-10 Aeromics, Inc. Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia
US10894055B2 (en) 2013-11-06 2021-01-19 Aeromics, Inc. Pharmaceutical compositions, methods of making pharmaceutical compositions, and kits comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}4-chlorophenyl dihydrogen phosphate
US11071744B2 (en) 2013-11-06 2021-07-27 Aeromics, Inc. Prodrug salts
US10258636B2 (en) 2013-11-06 2019-04-16 Aeromics, Inc. Prodrug salts
US11801254B2 (en) 2013-11-06 2023-10-31 Aeromics, Inc. Pharmaceutical compositions and methods of making pharmaceutical compositions comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate
US9827253B2 (en) 2013-11-06 2017-11-28 Aeromics, Inc. Prodrug salts
US12213987B2 (en) 2013-11-06 2025-02-04 Aeromics, Inc. Prodrug salts
US12496308B2 (en) 2013-11-06 2025-12-16 Aeromics, Inc. Methods of administering a pharmaceutically acceptable salt of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate
CN107207417A (zh) * 2014-11-13 2017-09-26 埃罗米克斯公司 新方法
WO2024172001A1 (ja) * 2023-02-13 2024-08-22 本岡 知子 抗トリパノソーマ薬

Also Published As

Publication number Publication date
KR20100097113A (ko) 2010-09-02
EP2201946A1 (en) 2010-06-30
CA2703494A1 (en) 2009-04-30
RU2010120675A (ru) 2011-11-27
EP2201946A4 (en) 2012-01-25
BRPI0816560A2 (pt) 2015-09-01
JPWO2009054439A1 (ja) 2011-03-03
CN101842093A (zh) 2010-09-22
JP5470046B2 (ja) 2014-04-16
CN101842093B (zh) 2012-08-22
CN102872020A (zh) 2013-01-16
AU2008314979A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
WO2009054439A1 (ja) Pai-1産生抑制剤
WO2008140066A3 (en) Pyridone derivatives as p38a mapk inhibitors
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
TN2011000362A1 (en) Pyridazinone compounds
MY150989A (en) Benzothiazole compounds useful for raf inhibition
TNSN08343A1 (en) Polycyclic cinnamide derivative
NO20080942L (no) Amino-5-[4-(difluormetoksy)-fenyl]-5-fenylimidazolonforbindelser som inhibitorer av beta-sekretase (BACE)
WO2007028135A3 (en) Imidazopyridine compounds
WO2008005368A3 (en) Piperazines as p2x7 antagonists
WO2009019005A8 (en) Tricyclic bridged cyclopentanedione derivatives as herbicides
WO2009019015A8 (en) Novel herbicides
WO2009030469A8 (en) Fungicidal 2-alkylthio-2-quinolinyloxy-acetamide deritvatives
WO2009001817A1 (ja) １１β－ＨＳＤ１阻害活性を有する化合物
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
WO2009038064A1 (ja) Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する複素環誘導体
BRPI0813870A2 (pt) Síntese catalisada por metal de transição de 2h-indazóis.
WO2008047952A3 (en) Antidepressant, neuroprotectant, amyloid beta deposition inhibitor or age retardant containing heterocyclic compound
IN2012DN00770A (ja)
TN2010000045A1 (en) Novel herbicides
WO2008153129A1 (ja) 尿酸値低下剤
WO2008136378A1 (ja) 新規なスルホンアミド誘導体またはその塩
WO2008078305A3 (en) 4-(1-amino-ethyl)-cyclohexylamine derivatives
BRPI0910761A2 (ja) The compound which has a NPY Y5 receptor-antagonism operation
WO2007062308A3 (en) Homo- and heterocyclic compounds suitable as cetp inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880113369.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08842108

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008842108

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008314979

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009538246

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2703494

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008314979

Country of ref document: AU

Date of ref document: 20081023

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107010934

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010120675

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0816560

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100414